Skip to main content
. 2021 May 18;5(10):2481–2489. doi: 10.1182/bloodadvances.2020003605

Table 2.

Cytogenetic characteristics of patients with inv(16) and those with t(8;21)

Characteristic inv(16) (n = 290) t(8;21) (n = 247) Total (N = 537) P
Presence of subclones .52
 No 204 (78) 172 (75) 376 (76)
 Yes 59 (22) 57 (25) 118 (24)
Presence of normal metaphases .52
 No 153 (55) 124 (52) 277 (57)
 Yes 108 (45) 100 (48) 208 (43)
Presence of secondary cytogenetic abnormality(s) <.01
 No 155 (58) 78 (34) 233 (47)
 Yes 113 (42) 154 (66) 267 (53)
Deletion of 7q .17
 No 250 (96) 209 (93) 459 (94)
 Yes 11 (4) 16 (7) 27 (6)
Trisomy 8 <.01
 No 220 (84) 209 (93) 529 (88)
 Yes 41 (16) 16 (7) 57 (12)
Deletion of 9q <.01
 No 260 (99.6) 192 (85) 452 (93)
 Yes 1 (0.4) 33 (15) 34 (7)
Trisomy 13 .09
 No 255 (98) 224 (99.6) 479 (99)
 Yes 6 (2) 1 (0.4) 7 (1)
Trisomy 21 <.01
 No 245 (94) 225 (100) 470 (97)
 Yes 16 (6) 0 (0) 16 (3)
Trisomy 22 <.01
 No 217 (83) 225 (100) 442 (91)
 Yes 44 (17) 0 (0) 44 (9)
Loss of X in females <.01
 No 123 (100) 57 (63) 180 (85)
 Yes 0 (0) 33 (37) 33 (15)
Loss of Y in males <.01
 No 120 (95) 71 (56) 191 (75)
 Yes 7 (5) 55 (44) 62 (25)
Other secondary abnormalities .30
 No 216 (83) 177 (79) 393 (81)
 Yes 45 (17) 47 (21) 92 (19)
Complex karyotype .02
 No 218 (84) 169 (75) 387 (80)
 Yes 42 (16) 55 (25) 97 (20)
Ploidy level <.01
 Hypodiploidy 7 (3) 87 (37) 94 (18)
 Pseudodiploidy 197 (72) 126 (54) 323 (64)
 Hyperdiploidy 68 (25) 22 (9) 90 (18)

Data are expressed as the number of patients affected (percentage of study subgroups and total). Bold P values are statistically significant.